Angiogenesis and apoptosis

Seminars in Cancer Biology

Volumn 13, Issue 2, 2003, Pages 159-167

  Folkman, Judah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Antiangiogenic chemotherapy; Apoptosis

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CYTOTOXICITY; ENDOTHELIUM CELL; GENE ACTIVITY; GROWTH INHIBITION; LABORATORY; MAXIMUM TOLERATED DOSE; NONHUMAN; ONCOGENE; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES;

EID: 0037376877     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00133-5     Document Type: Review

References (79)

1. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285:1971;1182-1186.
2. Folkman J. Tumor angiogenesis. In: Holland JF, Frei III E, Bast Jr RC, Kufe DW, Pollock RE, Weichselbaum RR, editors. Cancer medicine. 5th ed. Canada: B.C. Decker Inc.; 2000. p. 132-52.
3. Folkman J. Angiogenesis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's textbook of internal medicine. 15th ed. New York: McGraw-Hill; 2001. p. 517-30.
4. Achilles E.-G., Fernandez A., Allred E.N., Kisker O., Udagawa T., Beecken W.-D.et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. J. Natl. Cancer Inst. 93:2001;1075-1081.
5. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:1995;149-153.
6. Gimbrone M.A. Jr., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136:1972;261-276.
7. Udagawa T., Fernandez A., Achilles E.-G., Folkman J., D'Amato R.J. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of dormancy. FASEB J. 16(11):2002;1361-1370.
8. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315:1985;115-122.
9. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
10. Kandel J., Bossy-Wetzel E., Radvanyi F., Klagsbrun M., Folkman J., Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 66:1991;1095-1104.
11. Arbeit J.M., Olsen D.C., Hanahan D. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene. 13:1996;1847-1857.
12. Rak J., Yu J.L., Klement G., Kerbel R.S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J. Invest. Dermatol. Symp. Proc. 5:2000;24-33.
13. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90. Erratum in Nature 1998;395:525.
14. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E.C., Lu N.et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 94:1998;715-725.
15. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L.et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:2001;1194-1201.
16. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D.et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1999;1994-1998.
17. Rupnick M.A., Panigrahy D., Zhang C.-Y., Dallabrida S.M., Lowell B.B., Langer R.et al. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. U.S.A. 99:2002;10730-10735.
18. Hlatky L., Hahnfeldt P., Folkman J. clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 94:2002;883-893.
19. Streit M., Riccardi I., Velasco P., Brown L.F., Hawighorst T., Bornstein P.et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 96:1999;14888-14893.
20. Rak J.W., St. Croix B.D., Kerbel R.S. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs. 6:1995;3-18.
21. Hamada J., Cavanaugh P.G., Lotan O., Nicolson G.L. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br. J. Cancer. 66:1992;349-354.
22. Nicosia R.F., Tchao R., Leighton J. Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. Cancer Res. 43:1983;2159-2166.
23. Relf M., LeJeune S., Scott P.A.E., Fox S., Smith K., Leek R.et al. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:1997;963-969.
24. Kisker O., Onizuka S., Banyard J., Komiyama T., Becker C.M., Achilles E.G.et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 61:2001;7298-7304.
25. Teicher B.A., Dupuis N., Kusomoto T., Robinson M.F., Liu F., Menon K.et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat. Oncol. Invest. 2:1995;269-276.
26. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:1989;570-576.
27. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7:2001;987-989.
28. Herbst R.S., Mullani N.A., Davis D.W., Hess K.R., McConkey D.J., Charnsangavej C., O'Reilly M.S., Kim H.W., Baker C., Roach J., Ellis L.M., Rashid A., Pluda J., Bucana C., Madden T.L., Tran H.T., Abbruzzese J.L. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol. 20(18):2002;3804-3814.
29. Libutti S.K., Choyke P., Carrasquillo J.A., Bacharach S., Neumann R.D. Monitoring response to antiangiogenic agents using noninvasive imaging tests. Cancer J. Sci. Am. 5:1999;252-256.
30. Kurdziel K., Bacharach S., Carrasquillo J., Huebsch S., Whatley M., Sellers D.et al. Using PET 18F-FDG, 11CO, and 150-water for monitoring prostate cancer during a Phase II anti-angiogenic drug trial with thalidomide. Clin. Positron Imaging. 3:2000;144.
31. Choyke P.L., Knopp M.V., Libutti S.K. Special techniques for imaging blood flow to tumors. Cancer J. 8:2002;109-118.
32. Tozer G.M., Prise V.E., Wilson J., Cemazar M., Shan S., Dewhirst M.W.et al. Mechanisms associated with tumor vasculature shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61:2001;6413-6422.
33. Folkman J, Hahnfeldt P, Hlatky L. The logic of anti-angiogenic gene therapy. In: Friedman T, editor. The development of human gene therapy. New York: Cold Spring Harbor Laboratory Press; 1998. p. 527-43.
34. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G.et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1996;1843-1849.
35. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S.et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug resistant cancer. Cancer Res. 60:2000;1878-1886.
36. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J.et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J. Clin. Invest. 105:2000;R15-R24.
37. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
38. Gabra H., Cameron D.A., Lee L.E., Mackay J., Leonard R.C. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. Br. J. Cancer. 74:1996;2008-2012.
39. Hansen R.M., Ryan L., Anderson T., Krzywda B., Quebbeman E., Benson A. IIIet al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J. Natl. Cancer Inst. 88:1996;668-674.
40. Abu-Rustum N.R. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin. Oncol. 24:1997;62-67.
41. Loffler T.M., Freund W., Lipke J., Hausamen T.U. Schedule-and dose intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin. Oncol. 23:1996;32-34.
42. Kakolyris S., Samonis G., Koukourakis M., Vlachonicolis I., Chalkiadakis G., Kalbakis K.et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am. J. Clin. Oncol. 21:1998;505-508.
43. Chamberlain M.C. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch. 54:1997;554-558.
44. Neskovic-Konstantinovic Z.B., Bosnjak S.M., Radulovic S.S., Mitrovic L.B. Daily oral etoposide in metastatic breast cancer. Anticancer Drugs. 7:1996;L543-L547.
45. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J. Clin. Invest. 105:2000;1045-1047.
46. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2(10):2002;727-739.
47. Rak J., Yu J.L., Kerbel R.S., Coomber B.L. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res. 62:2002;1931-1934.
48. Fernandez A., Udagawa T., Schwesinger C., Beecken W.-D., Achilles E.G., McDonnell T.J.et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J. Natl. Cancer Inst. 93:2001;33-38.
49. Debinski W., Slagle-Webb B., Achen M.G., Stacker S.A., Tulchinsky E., Gillespie G.Y., Gibo D.M. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol. Med. 7(9):2001;598-608.
50. Arbiser J.L., Moses M.A., Fernandez C.A., Ghiso N., Cao Y., Klauber N.et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. U.S.A. 94:1997;861-866.
51. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N.et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
52. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
53. Viloria-Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Kerbel R.S. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumour cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumours. Am. J. Pathol. 151:1997;1523-1530.
54. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Schlaeppi J.M., Rak J.et al. Acquired resistance to the antitumour effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumour angiogenesis. Cancer Res. 61:2001;5090-5101.
55. Furuwatari C.et al. A comprehensive system to explore p53 mutations. Am. J. Clin. Pathol. 110:1998;368-373.
56. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 295:2002;1526-1528.
57. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1994;1582-1584.
58. Ravi R.et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1a. Genes Dev. 14:2000;34-44.
59. Zhang L.et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60:2000;3655-3661.
60. Sherif Z.A., Nakai S., Pirollo K.F., Rait A., Chang E.H. Down-modulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther. 8:2001;771-782.
61. Browder T., Folkman J., Hahnfeldt P., Heymach J., Hlatky L., Kieran M.et al. Antiangiogenic therapy and p53. Science. 297:2002;471a.
62. Kisker O., Becker C.M., Prox D., Fannon M., D'Amato R., Flynn E.et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61:2001;7669-7674.
63. Monestiroli S., Mancuso P., Burlini A., Pruneri G., Dell'Agnola C., Gobb A.et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61:2001;4341-4344.
64. Yang D.J., Kim K.D., Schechter N.R., Yu D.F., Wu P., Azhdarinia A.et al. Assessment of antiangiogenic effect using 99mTc-Ec-endostatin. Cancer Biother. Radiopharm. 17:2002;233-245.
65. Bergsmedh A., Szeles A., Henriksson M., Bratt A., Folkman J., Spetz A.-L.et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc. Natl. Acad. Sci. U.S.A. 98(11):2001;6407-6411.
66. Pulkkanen K.J., Laukkanen J.M., Fuxe J., Kettunen M.I., Rehn M., Kannasto J.M., Parkkinen J.J., Kauppinen R.A., Pettersson R.F., Yla-Herttuala S. The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther. 9(11):2002;908-916.
67. Blezinger P., Wang J., Gondo M., Quezada A., Mehrens D., French M.et al. Systemic inhibition of tumour growth and tumour metastases by intramuscular administration of the endostatin gene. Nat. Biotech. 17:1999;343-348.
68. Ding I., Sun J.Z., Fenton B., Liu W.M., Kimsely P., Okunieff P.et al. Intratumoural administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinoma. Cancer Res. 61(2):2001;526-531.
69. Read T.A., Sorensen D.R., Mahesparan R., Enger P.O., Timpl R., Olsen B.R.et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotech. 19:2001;29-34.
70. Joki T., Machluf M., Atala A., Zhu J., Seyfried N., Dunn I.F.et al. Continuous release of endostatin from microencapsulated engineered cells for tumour therapy. Nat. Biotech. 19:2001;35-39.
71. Kuo C.J., Farnebo F., Yu E.Y., Christofferson R., Swearingen R.A., Carter R.et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. U.S.A. 98(8):2001;4605-4610.
72. Feldman A.et al. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl. Cancer Inst. 93:2001;1014-1020.
73. Scappaticci F.A., Smith R., Pathak A., Schloss D., Lum B., Cao Y.et al. Combination angiostatin and endostatin gene transfer induces synergistic activity in vitro and antitumour efficacy in leukemia and solid tumours in mice. Mol. Ther. 3:2001;186-196.
74. Shi W., Teschendorf C., Muzyczka N., Siemann D.W. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther. 9:2002;513-521.
75. Calvo A., Feldman A., Libutti S.K., Green J.E. Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3 (1)/SV40 T-antigen transgenic mice. Cancer Res. 62:2002;3934-3938.
76. Indraccolo S., Gola E., Rosato A.et al. Differential effects of angiostatin, endostatin and interferon-alpha1 gene transfer on in vivo growth of human breast cancer cells. Gene Ther. 9:2002;867-887.
77. Pawliuk R., Bachelot R., Zurikiya O., Eriksson A., Cao Y., Leboulch P. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol. Ther. 5:2002;345-351.
78. Eisterer W.et al. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther. 5:2002;352-359.
79. Slaton J.W., Perrotte P., Inoue K., Dinney C.P.N., Fidler I.J. Interferon alpha mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5:1999;2726-2734.